The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Insights and Forecast to 2028
Synopsis
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
Market Analysis and Insights: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market
The global Duchenne Muscular Dystrophy (DMD) Therapeutics market size is projected to reach US$ 15940 million by 2028, from US$ 1329.2 million in 2021, at a CAGR of 42.1% during 2022-2028.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market.
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Scope and Market Size
Duchenne Muscular Dystrophy (DMD) Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Exondys
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
By Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
Market Analysis and Insights: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market
The global Duchenne Muscular Dystrophy (DMD) Therapeutics market size is projected to reach US$ 15940 million by 2028, from US$ 1329.2 million in 2021, at a CAGR of 42.1% during 2022-2028.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market.
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Scope and Market Size
Duchenne Muscular Dystrophy (DMD) Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Exondys
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
By Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Index1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2017-2028)
2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
2.2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
2.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
2.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
2.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
2.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue
3.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2021
3.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Head office and Area Served
3.6 Key Players Duchenne Muscular Dystrophy (DMD) Therapeutics Product Solution and Service
3.7 Date of Enter into Duchenne Muscular Dystrophy (DMD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2023-2028)
5 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2017-2028)
6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
6.2.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022)
6.2.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028)
6.2.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
6.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022)
6.3.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028)
6.3.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
6.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
6.4.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022)
6.4.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2017-2028)
7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
7.2.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022)
7.2.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028)
7.2.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
7.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022)
7.3.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028)
7.3.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
7.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
7.4.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022)
7.4.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
8.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2017-2028)
9.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
9.2.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022)
9.2.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028)
9.2.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
9.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
9.3.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022)
9.3.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028)
9.3.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
9.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
9.4.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022)
9.4.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
10.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.1.5 Sarepta Therapeutics Recent Developments
11.2 PTC Therapeutics
11.2.1 PTC Therapeutics Company Details
11.2.2 PTC Therapeutics Business Overview
11.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.2.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.2.5 PTC Therapeutics Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.3.4 Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.3.5 Pfizer Recent Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.4.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.4.5 Bristol-Myers Squibb Recent Developments
11.5 Italfarmaco
11.5.1 Italfarmaco Company Details
11.5.2 Italfarmaco Business Overview
11.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.5.4 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.5.5 Italfarmaco Recent Developments
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Details
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.6.5 Santhera Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Exondys
Table 3. Key Players of Emflaza
Table 4. Key Players of Translarna
Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2017-2022)
Table 9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2023-2028)
Table 11. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
Table 12. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
Table 13. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
Table 14. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Players (2017-2022)
Table 17. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2021)
Table 18. Ranking of Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Duchenne Muscular Dystrophy (DMD) Therapeutics Product Solution and Service
Table 22. Date of Enter into Duchenne Muscular Dystrophy (DMD) Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2017-2022)
Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2023-2028)
Table 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2017-2022)
Table 30. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2023-2028)
Table 32. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 62. Sarepta Therapeutics Company Details
Table 63. Sarepta Therapeutics Business Overview
Table 64. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 65. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 66. Sarepta Therapeutics Recent Developments
Table 67. PTC Therapeutics Company Details
Table 68. PTC Therapeutics Business Overview
Table 69. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 70. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 71. PTC Therapeutics Recent Developments
Table 72. Pfizer Company Details
Table 73. Pfizer Business Overview
Table 74. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 75. Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 76. Pfizer Recent Developments
Table 77. Bristol-Myers Squibb Company Details
Table 78. Bristol-Myers Squibb Business Overview
Table 79. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 80. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 81. Bristol-Myers Squibb Recent Developments
Table 82. Italfarmaco Company Details
Table 83. Italfarmaco Business Overview
Table 84. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 85. Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 86. Italfarmaco Recent Developments
Table 87. Santhera Pharmaceuticals Company Details
Table 88. Santhera Pharmaceuticals Business Overview
Table 89. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 90. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 91. Santhera Pharmaceuticals Recent Developments
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Exondys Features
Figure 3. Emflaza Features
Figure 4. Translarna Features
Figure 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2021 VS 2028
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Home Care Case Studies
Figure 9. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
Figure 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2021 VS 2028
Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players in 2021
Figure 14. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2021
Figure 16. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 17. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 18. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 19. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Country (2017-2028)
Figure 20. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 23. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 24. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 25. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Country (2017-2028)
Figure 26. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 33. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 34. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 35. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Region (2017-2028)
Figure 36. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 43. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 44. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 45. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Country (2017-2028)
Figure 46. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 50. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 51. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Country (2017-2028)
Figure 52. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
Figure 56. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
Figure 57. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
Figure 58. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
Figure 59. Italfarmaco Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
Figure 60. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
